Investigators sought to assess outcomes following CD19 CAR T-cell therapy in children and young adults who underwent alloHSCT for B-cell acute lymphoblastic leukemia.
A team of investigators report on their validated nomogram that incorporates pleural effusion into the classification of disease severity in patients with multiple myeloma.
A retrospective, single-center crossover study was conducted that compared rates of infection in patients with multiple myeloma during observation compared with those receiving IVIG.
Investigators conducted a study to determine the incidence and clinical course of BK virus hemorrhagic cystitis in children undergoing hematopoietic cell transplantation.
Researchers sought to determine whether adding ixazomib to treatment with lenalidomide plus dexamethasone would give a benefit to patients with newly diagnosed multiple myeloma.
A team of investigators assessed the application of whole-genome sequencing for genomic profiling of patients with acute myeloid leukemia or myelodysplastic syndromes.
Investigators conducted a phase IIb study to assess the safety and efficacy of umbralisib 800 mg/d in patients with relapsed or refractory non-Hodgkin lymphoma.
A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma.
A single-arm, phase 2 trial was conducted to assess response to treatment with carfilzomib plus cyclophosphamide and dexamethasone among patients with relapsed/refractory multiple myeloma.
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
A multicenter, randomized, phase 3 trial compared blinatumomab with intensive multidrug consolidation chemotherapy in children with high-risk, first-relapse B-cell ALL.
Researchers sought to determine whether molecular characteristics could help predict responses to treatments with venetoclax in patients with relapsed or refractory AML.
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
Researchers sought to determine whether paroxysmal nocturnal hemoglobinuria clones might predict treatment responses for patients with MDS and aplastic anemia.
